<DOC>
	<DOC>NCT01481701</DOC>
	<brief_summary>This is a Phase II study for recurrent ovarian carcinoma platinum-sensitive and resistant tumors Folfox regimen.</brief_summary>
	<brief_title>A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma</brief_title>
	<detailed_description>Evaluation of the safety and the efficacy of a combination of oxaliplatin and 5FU (Folfox) in patients with ovarian carcinoma relapsing either after platinum-combined regimen. The Folfox regimen is administered every 14 days. Evaluation of the toxicity is performed at each cycle and evaluation of the efficacy every 4 cycles of chemotherapy.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>ovarian carcinoma relapse neurotoxicity grade III renal clearance &lt; 60 ml/min</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>ovarian carcinoma</keyword>
	<keyword>Bordet</keyword>
	<keyword>relapse</keyword>
</DOC>